Von Hippel-Lindau disease: A new approach to an old problem

International Journal of Endocrinology and Metabolism

Volumn 10, Issue 4, 2012, Pages 619-624

  Tootee, Ali ^a   Hasani Ranjbar, Shirin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Pheochromocytoma; Von Hippel Lindau disease

Indexed keywords

ANGIOGENESIS INHIBITOR; MESSENGER RNA; METADRENALIN;

ADRENALECTOMY; AUDIOMETRY; CAUSAL ATTRIBUTION; CLINICAL FEATURE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; FAMILY HISTORY; GENE; GENE FUNCTION; GENE INACTIVATION; GENE LOCATION; GENE MUTATION; GENETIC SCREENING; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; KIDNEY CYST; NEPHRON SPARING SURGERY; PANCREAS DISEASE; PATHOGENESIS; PATIENT REFERRAL; PHEOCHROMOCYTOMA; POSTOPERATIVE COMPLICATION; PROGNOSIS; RADIOFREQUENCY ABLATION; RETINAL HEMANGIOBLASTOMA; REVIEW; SCREENING TEST; VHL GENE; VISUAL SYSTEM EXAMINATION; VON HIPPEL LINDAU DISEASE;

EID: 84872507861     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/ijem.4510     Document Type: Review

References (28)

1. Hasani-Ranjbar S, Amoli MM, Ebrahim-Habibi A, Haghpanah V, Hejazi M, Soltani A, et al. Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease. Fam Cancer. 2009;8 (4):465-71.
2. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 1993;329 (21):1531-8.
3. Shuin T, Yamasaki I, Tamura K, Okuda H, Furihata M, Ashida S. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol. 2006;36 (6):337-43.
4. Inglese M. Von Hippel-Lindau disease: an overview. Nephrol Nurs J. 2007;34 (4):390-3; quiz 4.
5. Kaelin WG, Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol. 2003;14 (11):2703-11.
6. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361 (9374):2059-67.
7. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat gene. 2002;32 (4):614-21.
8. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260 (5112):1317-20.
9. Akcaglar S, Yavascaoglu I, Vuruskan H, Oktay B. Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis. Int Urol Nephrol. 2008;40 (3):615-20.
10. Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta. 1996;1242 (3):201-10.
11. Poulsen ML, Gimsing S, Kosteljanetz M, Moller HU, Brandt CA, Thomsen C, et al. von Hippel-Lindau disease: surveillance strategy for endolymphatic sac tumors. Genet Med. 2011;13 (12):1032-41.
12. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2 (9):673-82.
13. Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Baba M, et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem. 2001;276 (47):43611-7.
14. Schnell PO, Ignacak ML, Bauer AL, Striet JB, Paulding WR, Czyzyk-Krzeska MF. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxiainducible transcription factors. J Neurochem. 2003;85 (2):483-91.
15. Casarin A, Martella M, Polli R, Leonardi E, Anesi L, Murgia A. Molecular characterization of large deletions in the von Hippel-Lindau (VHL) gene by quantitative real-time PCR: the hypothesis of an alu-mediated mechanism underlying VHL gene rearrangements. Mol Diagn Ther. 2006;10(4):243-9.
16. Barron J. Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis. J Clin Pathol. 2010;63 (8):669-74.
17. Sun Y, Sun Q, Shen J, Wu H, Guan Y, Gong K, et al. Cauda equina hemangioblastoma at L5 vertebral level related to von Hippel-Lindau disease. Br J Neurosurg. 2011.
18. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77 (283):1151-63.
19. Wind JJ, Lonser RR. Management of von Hippel-Lindau diseaseassociated CNS lesions. Expert Rev Neurother. 2011;11 (10):1433-41.
20. Hasani-Ranjbar S, Ebrahim-Habibi A, Larijani B. Familial Catecholamine-Secreting Tumors-Three Distinct Families with Hereditary Pheochromocytoma. INTECH.150-65.
21. Benhammou JN, Boris RS, Pacak K, Pinto PA, Linehan WM, Bratslavsky G. Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. J Urol. 2010;184 (5):1855-9.
22. Jilg CA, Neumann HP, Glasker S, Schafer O, Ardelt PU, Schwardt M, et al. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma. Urol Int. 2012;88 (1):71-8.
23. Zhang J, Pan JH, Dong BJ, Xue W, Liu DM, Huang YR. Active surveillance of renal masses in von Hippel-Lindau disease: growth rates and clinical outcome over a median follow-up period of 56 months. Fam Cancer. 2012;11 (2):209-14.
24. Arjumand W, Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol. 2012;33 (1):9-16.
25. Safo AO, Pambuccian SE. Pancreatic manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med. 2010;134 (7):1080-3.
26. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol. 2003;21 (20):3770-6.
27. Lara PN, Jr., Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005;11 (12):4444-50.
28. Chung DC, Haber DA. Principles of Clinical Cancer Genetics. Springer New York Dordrecht Heidelberg London 2010